Phase 3Not yet recruiting

Dapagliflozin for Long COVID Syndrome (DALCO)

Sponsor
Ottawa Heart Institute Research Corporation (Academic or other)
Enrollment
192 planned
Conditions
COVID - 19; Long COVID Syndrome; SARS CoV-2
Interventions
Dapagliflozin (DAPA); Placebo
Ages
adults, older adults
Registry
NCT06907251

Full record on ClinicalTrials.gov

From the registry

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

Primary outcomes

  • 6 month change in EQ-5D derived utility score.

History

  1. Study completion expected

  2. Primary completion expected

  3. Expected to start

  4. Last registry update

  5. Registered